The DOI matches its Crossref record; 66 of the 66 references it cites were found in a registry or an index.
Microbiome alteration via fecal microbiota transplantation is effective for refractory immune checkpoint inhibitor–induced colitis
Open accessAbstract
Immune checkpoint inhibitors (ICIs) target advanced malignancies with high efficacy but also predispose patients to immune-related adverse events like immune-mediated colitis (IMC). Given the association between gut bacteria with response to ICI therapy and subsequent IMC, fecal microbiota transplantation (FMT) represents a feasible way to manipulate microbial composition in patients, with a potential benefit for IMC. Here, we present a large case series of 12 patients with refractory IMC who underwent FMT from healthy donors as salvage therapy. All 12 patients had grade 3 or 4 ICI-related diarrhea or colitis that failed to respond to standard first-line (corticosteroids) and second-line immunosuppression (infliximab or vedolizumab). Ten patients (83%) achieved symptom improvement after FMT, and three patients (25%) required repeat FMT, two of whom had no subsequent response. At the end of the study, 92% achieved IMC clinical remission. 16 S rRNA sequencing of patient stool samples revealed that compositional differences between FMT donors and patients with IMC before FMT were associated with a complete response after FMT. Comparison of pre- and post-FMT stool samples in patients with complete responses showed significant increases in alpha diversity and increases in the abundances of Collinsella and Bifidobacterium , which were depleted in FMT responders before FMT. Histologically evaluable complete response patients also had decreases in select immune cells , including CD8 + T cells, in the colon after FMT when compared with non-complete response patients ( n = 4). This study validates FMT as an effective treatment strategy for IMC and gives insights into the microbial signatures that may play a critical role in FMT response.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The therapeutic mechanism of FMT appears multifaceted, involving not only the restoration of microbial richness but also immune modulation, as evidenced by reductions in CD8+ cytotoxic T cells and shifts in the Treg-to–cytotoxic T cell ratio within affected colonic tissues (Halsey et al., 2023).”
From Microbiota-centered interventions to boost immune checkpoint blockade therapies (2025) · cites this paper as Halsey et al., 2023
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Controlling the False Discovery Rate: A Practical and Powerful Approach to Multiple Testing
Benjamini, Y., & Hochberg, Y. (1995) · Journal of the Royal Statistical Society Series B: Statistical Methodology · doi:10.1111/j.2517-6161.1995.tb02031.x · Cited by 109,482
Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2
Love, M. I., Huber, W., & Anders, S. (2014) · Genome Biology · doi:10.1186/s13059-014-0550-8 · Cited by 95,106
Schloss, P. D., Westcott, S. L., Ryabin, T., Hall, J. R., Hartmann, M., Hollister, E. B., Lesniewski, R. A., Oakley, B. B., Parks, D. H., Robinson, C. J., et al. (2009) · Applied and Environmental Microbiology · doi:10.1128/aem.01541-09 · Cited by 19,549
VSEARCH: a versatile open source tool for metagenomics
(2016) · doi:10.7717/peerj.2584 · Cited by 10,773
Pruesse, E., Quast, C., Knittel, K., Fuchs, B. M., Ludwig, W., Peplies, J., & Glöckner, F. O. (2007) · Nucleic Acids Research · doi:10.1093/nar/gkm864 · Cited by 6,682
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
Gopalakrishnan, V., Spencer, C. N., Nezi, L., Reuben, A., Andrews, M. C., Karpinets, T. V., Prieto, P. A., Vicente, D., Hoffman, K., Wei, S. C., et al. (2018) · Science · doi:10.1126/science.aan4236 · Cited by 4,812
Self-citationInteraction between microbiota and immunity in health and disease
Zheng, D., Liwinski, T., & Elinav, E. (2020) · Cell Research · doi:10.1038/s41422-020-0332-7 · Cited by 3,947
The gut microbiota--masters of host development and physiology
Sommer, F., & Bäckhed, F. (2013) · Nature Reviews Microbiology · doi:10.1038/nrmicro2974 · Cited by 3,681
Anticancer immunotherapy by CTLA-4 blockade relies on the gut microbiota
Vétizou, M., Pitt, J. M., Daillère, R., Lepage, P., Waldschmitt, N., Flament, C., Rusakiewicz, S., Routy, B., Roberti, M. P., Duong, C. P. M., et al. (2015) · Science · doi:10.1126/science.aad1329 · Cited by 3,488
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Matson, V., Fessler, J., Bao, R., Chongsuwat, T., Zha, Y., Alegre, M.-L., Luke, J. J., & Gajewski, T. F. (2018) · Science · doi:10.1126/science.aao3290 · Cited by 3,107
Cited by
Sorted by citations
Items 101–161 of 161
The Immune Checkpoint Inhibitors Journey: From Early Promise to Lasting Impact
Hajjar, J., Stephen, B., Aaroe, A., Aiche, M. M., Al-Zubidi, N. S., Ameri, M., Brooks, K. A., Carabenciov, I. D., Chambers, M. S., Chaudhry, A. L., et al. (2026) · Journal of Immunotherapy and Precision Oncology · doi:10.36401/jipo-26-12 · Cited by 3
Self-citationItoh, K., & Matsueda, S. (2024) · Biomedicines · doi:10.3390/biomedicines12040803 · Cited by 3
From Innovation to Complication: A Case Report and Review on Immune-Related Colitis Induced by ICIs
Li, H., Pan, Y., Liu, W., Zhang, H., Tian, X., Zhao, R., & Zhu, Y. Z. (2025) · Pharmaceuticals · doi:10.3390/ph18081211 · Cited by 3
Allergy-associated biomarkers in early life identified by Omics techniques
Zubeldia‐Varela, E., Ibáñez-Sandín, M. D., Gómez‐Casado, C., & Pérez‐Gordo, M. (2024) · Frontiers in Allergy · doi:10.3389/falgy.2024.1359142 · Cited by 3
Dong, H., Peng, Y., Wang, X., & Cui, H. (2025) · Frontiers in Immunology · doi:10.3389/fimmu.2025.1551445 · Cited by 3
Immune Checkpoint Inhibitor–Induced Colitis
Thomas, A. S., Yang, L., Campbell, M., Thompson, J. A., Tan, D., Faleck, D. M., & Wang, Y. (2024) · Gastroenterology · doi:10.1053/j.gastro.2024.09.034 · Cited by 3
Self-citationHillege, L. E., Trepka, K. R., Ziemons, J., Aarnoutse, R., Guthrie, B. G. H., de Vos‐Geelen, J., Iersel, L. V., van Hellemond, I. E. G., Baars, A., Vestjens, J. H. M. J., et al. (2024) · medRxiv · doi:10.1101/2024.10.11.24315249 · Cited by 3
Ziogas, D. C., Theocharopoulos, C., Martinos, A., Lyrarakis, G., Stefanou, D. T., Anastasopoulou, A. N., & Gogas, H. (2026) · Current Oncology Reports · doi:10.1007/s11912-026-01744-z · Cited by 2
The relationship between gut microbiota and cancer immune response and immunotherapy
Jia, Y., Liu, Y., & Liu, J. Q. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1833138 · Cited by 2
Precision nutrition in gastric cancer: current advances and future directions
Wang, Z., L, L., & Mao, J. (2026) · Frontiers in Nutrition · doi:10.3389/fnut.2026.1844696 · Cited by 2
Faecal transplantation: the good, the bad and the ugly
Sin, H. C. L., & Haifer, C. (2024) · Internal Medicine Journal · doi:10.1111/imj.16559 · Cited by 1
Management of refractory checkpoint inhibitor-induced colitis
Zaher, A., Santos, M. J. M. N., Elsaygh, H., Peterson, S. J., Cruz, C. C., Thomas, A. S., & Wang, Y.-H. (2025) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2025.2496431 · Cited by 1
Self-citationShatila, M., Abdul-Baki, K., Rivera, A. C. U., Takigawa, K., Lee, I. J.-A., Sullivan, A., Gupta, T., Lu, L., Menon, R., Khan, A., et al. (2025) · Cancer Medicine · doi:10.1002/cam4.71123 · Cited by 1
Self-citationBiscaglia, G., Gentile, A., Parente, P., Calvo, A., Fontana, R., Continisio, A., Brina, A. L. P. D., Ciardiello, D., McIlwain, G., Latiano, A., et al. (2025) · Nutrients · doi:10.3390/nu17233788 · Cited by 1
Digestive System Toxicities of Immune Checkpoint Inhibitors: Mechanisms and Clinical Implications
Lin, A., Huang, Q., Zhang, J., & Luo, P. (2026) · BIO Integration · doi:10.15212/bioi-2025-0169 · Cited by 1
Kleinhans, M., Lissen, A., Hewitson, L., & Rijkers, G. T. (2026) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2026.2621240 · Cited by 1
Gut Microbiome Strategies for Enhancing ICI Delivery Across the BBB in Glioblastoma
Barati, S., Ghoflchi, S., Nakhaei, A., Yazdi, M., Hosseinzadeh, P., Hosseini, H., & Jalili‐Nik, M. (2026) · BioFactors · doi:10.1002/biof.70077 · Cited by 1
Liu, X., Chen, Z., Lu, Y., Wu, Y., Huang, Y., Zhang, Y., Li, M., & Feng, N. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1756107 · Cited by 1
Diop, K., Benlaïfaoui, M., Hunter, S., Méndez-Salazar, E. O., Hakozaki, T., Richard, C., Prifti, D. K., Kourtian, S., Proulx-Rocray, F., Naimi, S., et al. (2026) · Microbiome · doi:10.1186/s40168-026-02419-4 · Cited by 2
Pan, Y., Yuan, Z., Cao, X., Zhao, H., Shi, W., Chen, Y., & Gong, A. (2026) · International Immunopharmacology · doi:10.1016/j.intimp.2026.116874 · Cited by 1
The intratumoral microbiota: from origin and identification to function and therapeutic perspective
Guo, F., Zhuang, W., Huang, J., Dong, Y., & Xie, H. (2026) · Acta Biochimica et Biophysica Sinica · doi:10.3724/abbs.2026098 · Cited by 1
Decoding the microbiome-immune crosstalk in cancer: from mechanisms to therapeutic translation
Zhao, N., Wu, L., Peng, S., Yang, H., 宋永春, Zhang, Y., & Ding, L. (2026) · Biomarker Research · doi:10.1186/s40364-026-00930-2 · Cited by 2
Huang, M., Liu, Y., Lu, H., Wang, W., Gao, H., Qiu, J., Jin, Y., & Ren, Q. (2026) · Microbiota Medicine Research · doi:10.1002/mmr3.70011 · Cited by 1
Wang, Y., Fan, C., Varatharajalu, K., Satila, M., Cruz, C. C., Sun, B., Lermi, N. O., Hayase, T., Thomas, A., Szymonowicz, K., et al. (2026) · Cell Reports Medicine · doi:10.1016/j.xcrm.2026.103044 · Cited by 1
Self-citationFecal Microbiota Transplantation
Singh, B., Mal, G., Kalra, R. S., & Marotta, F. (2024) · Springer eBooks · doi:10.1007/978-3-031-65459-6_36
Characteristics and dynamic changes of gut microbiota in Mongolian horses and Guizhou horses
Li, Y., & Lan, Y. (2025) · Frontiers in Microbiology · doi:10.3389/fmicb.2025.1582821
Recurrent Clostridioides Difficile Infection and Colitis Post Immune Checkpoint Inhibitor Therapy
Baerman, E. A., Junek, K., Lavilla, R. C., Wang, X. S., & Wang, Y. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_23
Self-citationImmune Checkpoint Inhibitor Use in Patients with Pre-Existing Inflammatory Bowel Disease
Faleck, D. M., Srivastava, A., & Eng, J. (2025) · Springer eBooks · doi:10.1007/978-3-031-83533-9_26
Microbiota targets in immune checkpoint therapy: How far are we from clinical application?
Zou, T., Tan, J., Chen, Y., & Jingyuan, F. (2025) · Chinese Medical Journal · doi:10.1097/cm9.0000000000003668
Potential missed opportunities to improve long-term liver allograft health
Fallahzadeh, M. A., McCaughan, G. W., & O’Leary, J. G. (2025) · Liver Transplantation · doi:10.1097/lvt.0000000000000720
Living therapeutics: Colorectal related diseases precision therapy with engineered organisms
Huang, J., Lan, Y., Chen, L., Guan, X., Liang, R., Liang, J., Gao, M., Gan, J., Guo, Y., & Zhang, S. (2025) · Chinese Chemical Letters · doi:10.1016/j.cclet.2025.112151
Gastrointestinal complications of immune checkpoint Inhibitor therapy
Carbonnel, F., Martin, A., Marthey, L., Bellanger, C., Bou-Farah, R., Boytchev, I., Abdallah, R., Amiot, A., & Meyer, A. (2025) · La Presse Médicale · doi:10.1016/j.lpm.2025.104326
Toxicité digestive « supérieure » de l’immunothérapie
Vivier-Chicoteau, J., Thibault, L., Vaflard, P., du Rusquec, P., Seban, R., Daniel, C., Mariani, P., Loirat, D., & Buecher, B. (2025) · Bulletin du Cancer · doi:10.1016/j.bulcan.2025.09.002
Identification and Evaluation of Benzimidazole- Agonists of Innate Immune Receptor NOD2
Wittle, L. E., Ocius, K. L., Chordia, M. D., Wagoner, C. M. V., Bullock, T. N. J., & Pires, M. M. (2026) · ACS Infectious Diseases · doi:10.1021/acsinfecdis.5c00737
Xu, B., Liu, P., Yan, N., Wang, T., Liu, L., & Cheng, Y. (2025) · Immunotherapy · doi:10.1080/1750743x.2026.2618937 · Cited by 1
Wang, Z., Chen, Z., Ye, T., Fan, J., Cai, Y., Zhou, H., Ou, T., Lu, D. S., & Cai, K. (2026) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1093/ajrcmb/aanag010
Halle, Ž. B., Tomašić, V., Bišćanin, A., Čačić, P., Saric, I., Mustapić, S., Stojić, J., Luetić, K., Bekić, D., Paić, M., et al. (2026) · Biomedicines · doi:10.3390/biomedicines14030683
Immunology biomarkers in cancer
Fernandes, C., Mahale, M., Thakur, S., Patel, P. A., & Kaul, R. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-44041-0.00020-9
Moura, M. J., Chatterjee, A., Wali, S., Garza, D. M., Salim, H., Rong, J., Menon, R., Jafri, F. I., Rivera, A. C. U., Mortan, R. E., et al. (2026) · Expert Opinion on Drug Safety · doi:10.1080/14740338.2026.2659253
Self-citationMicrobiome-targeted therapeutics in head & neck cancer
Choudhury, M., & Tavassoli, M. (2026) · Advances in immunology · doi:10.1016/bs.ai.2026.03.012
Anti-Cancer Effects of Quercetin: What Role Does the Gut Microbiota Play?
Yi, G., Liu, Y., Li, G., & Chang, K. (2026) · Molecules · doi:10.3390/molecules31091456
Zheng, H., Lai, C., Liu, F., & Luo, H. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1817557
Krausz, M., Zhao, B., Mrovecova, P., Proietti, M., & Grimbacher, B. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.05.18.726014
Wang, Y., Li, Z., & Kong, X. (2026) · Cancer Screening and Prevention · doi:10.14218/csp.2026.00033
Self-citationThe role of gut microbiota in cancer development and translational modulation strategies
Bai, X., Kang, X., & Wong, S. H. (2026) · Elsevier eBooks · doi:10.1016/b978-0-443-40306-4.00017-x
Application and prospects of fecal microbiota transplantation in cancer therapy
Fan, Y., Li, Y., Bi, H.-Y., Ding, Y., Lyu, L., Geng, Y., & Fu, W. (2026) · Frontiers in Cellular and Infection Microbiology · doi:10.3389/fcimb.2026.1880573
Microbiome Stewardship: re-defining high-risk antibiotics
Eubank, T. A., Msdi, A. S., & Garey, K. W. (2026) · Anaerobe · doi:10.1016/j.anaerobe.2026.103072
The microbiome determines the phenotype in CTLA-4 insufficient mice and menPreprint
Zhao, B., Stopp, L., Sivapornnukul, P., Lagies, S., Huang, K. D., Lesker, T. R., Andreani, V., Giri, R., Mrovecova, P., Schifferdecker, W., et al. (2026) · bioRxiv (Cold Spring Harbor Laboratory) · doi:10.64898/2026.08.14.742114
Ma, S., Rong, J., Wu, X., Wu, X., Gao, Y., Li, H., & Yan, T. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1852152
Jin, J., Zheng, L., Tian, Y., Chu, M., & Cao, B. (2026) · Frontiers in Medicine · doi:10.3389/fmed.2026.1943642
B cell-guided inflammatory cascade perpetuates ICI-mediated colitis
Turner, N., Keam, S., Abdel‐Wahab, N., Colunga-Minutti, J., Trejo, C. A., Kugeratski, F. G., Pilato, M. D., Gutierrez, J. M. S., Haymaker, C., Shalapour, S., et al. (2026) · Cell Reports · doi:10.1016/j.celrep.2026.117969
Lu, J., Xuan, M., Yu, L., Xie, Z., Chu, Q., Wei, S., Wang, T., Xue, C., & Li, L. (2026) · MedComm · doi:10.1002/mco2.70994
Gut microbiome in immuno-oncology: potential for clinical exploitation
Margarita, E., Saito, K., Bisegna, P., Ferrari, M., Valeriani, E., Guerrieri, M., Funaro, B., Feliciani, D., Gasbarrini, A., Porcari, S., et al. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102143
Cancer and the microbiome: from association to intervention
Moradi, A., Winayak, R., & Pal, S. K. (2026) · The Lancet Oncology · doi:10.1016/s1470-2045(26)00326-8
Immune‐Cell Dynamics in the Tumor Microenvironment: Implications for Cancer Therapy
Pin, G., Xie, Y., Song, R., Yang, M., Lin, Z., Guan, C., Wang, Z., Wen, J., & Chen, G. (2026) · MedComm · doi:10.1002/mco2.71040
Gut microbiota in esophageal cancer: mechanisms, clinical implications, and therapeutic potential
Li, Y., Zhou, L., Huang, R., Wang, Y., 赵海滨, Sun, M., Zhang, Y., 吴仲兵, & Li, J. (2026) · Frontiers in Microbiology · doi:10.3389/fmicb.2026.1955627
Self-citationZhang, L., Du, X., Sun, L., Shi, Z., & Nie, Y. (2026) · Microbiota Medicine Research · doi:10.1002/mmr3.70015
ZHANG, Y.-F., Ran, X. U. E., & Lin, S. H. E. N. (2026) · Shengming kexue · doi:10.3724/cbls.2026124
Frandsen, E. V., Hvas, C. L., Baunwall, S. M. D., Friis, R. B., Guldbrandt, L. M., & Schmidt, H. (2026) · Best Practice & Research Clinical Gastroenterology · doi:10.1016/j.bpg.2026.102152
From Dysbiosis to Symbiosis: Using the Gut Microbiome to Improve Cancer Outcomes
Nassar, S. A. (2026) · Medical Sciences · doi:10.3390/medsci14060669
Zhang, R., Zhang, X., He, X., & Xiang, M. (2026) · Frontiers in Immunology · doi:10.3389/fimmu.2026.1983756
Metadata
- Authors
- Halsey, T. M., Thomas, A. S., Hayase, T., Ma, W., Abu-Sbeih, H., Sun, B., Parra, E. R., Jiang, Z.-D., DuPont, H. L., Sanchez, C., El-Himri, R., Brown, A., Flores, I., McDaniel, L., Ortega Turrubiates, M., Hensel, M., Pham, D., Watowich, S. S., Hayase, E., Chang, C.-C., Jenq, R. R., & Wang, Y.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Department of Gastroenterology, Hepatology and Nutrition, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
- Center for Infectious Diseases, School of Public Health, University of Texas, Houston, TX 77054, USA.
- Kelsey Research Foundation (US)
- Department of Genomic Medicine, University of Texas MD Anderson Cancer Center, Houston, TX 77054, USA.
- Middlebury College (US)
- Corresponding author
- Halsey, Taylor M.
- Thomas, Anusha S.
- Jenq, Robert R.
- Wang, Yinghong
- ORCID
- Venue
- Science Translational Medicine
- Published
- 2023-06-14
- Volume
- 15
- Issue
- 700
- Pages
- eabq4006-eabq4006
- ISSN
- 1946-6234 (ISSN-L)
- 1946-6242
- PMC
- PMC10759507
- OpenAlex
- W4380590697
- Cited by
- 161
- References
- 66
- Citations by year
- 2026: 54 · 2025: 55 · 2024: 47 · 2023: 5
- FWCI
- 19.55
- Type
- journal article
- Language
- en
- Open access
- hybrid
- doi.org
- Licence
- cc-by
- Locations
- Science Translational Medicine (publishedVersion, cc-by)
- PubMed (publishedVersion)
- PubMed Central (acceptedVersion)
- Digital Commons-TMC (Texas Medical Center) (submittedVersion)
- Funders
- Cancer Prevention and Research Institute of Texas (RP210042)
- Seres Therapeutics
- University of Texas MD Anderson Cancer Center
- National Heart, Lung, and Blood Institute (R01HL124112)
- National Cancer Institute (P30CA016672)
- Moonshot Research and Development Program
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Gut microbiota and health
- Health Sciences › Medicine › Gastroenterology › Inflammatory Bowel Disease
- Keywords
- fecal microbiota transplantation, immune checkpoint inhibitors, immune-related colitis, immune-related adverse events, refractory colitis, gut microbiota, microbial signatures, Collinsella, Bifidobacterium, alpha diversity, CD8+ T cells, immunosuppressive therapy
- MeSH terms
- Fecal Microbiota Transplantation, Immune Checkpoint Inhibitors, Aged, Colitis, Feces, Female, Humans, Male, Middle Aged, RNA, Ribosomal, 16S
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
